- Home
- APRE vs ALBT Comparison
APRE vs ALBT Comparison
Compare APRE & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | ALBT |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APRE | ALBT |
|---|---|---|
| Price | $0.84 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 77.0K | ★ 119.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $488,239.00 | ★ $1,611,940.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $0.80 |
| 52 Week High | $4.65 | $11.66 |
Technical Indicators
Market Signals| Indicator | APRE | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 33.19 | 27.76 |
| Support Level | $0.89 | $0.80 |
| Resistance Level | $0.91 | $1.19 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.99 | 0.92 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.